Loading...
One glucagon-like peptide-1 (GLP-1) agonist, liraglutide (Saxenda), is approved for treating obesity. Now, another GLP-1 agonist, semaglutide (marketed for diabetes as Ozempic), has been examined in an industry-supported obesity-treatment trial that involved nearly 2000 nondiabetic obese adults (mean body-mass index, 38 m/kg2; mean weight, 105 kg). Patients were randomized to receive either semaglutide or placebo, given once weekly by injection; an initial semaglutide dose of 0.25 mg was titrated during 4 months to a maximal dose of 2.4 mg if tolerated. (Note: the maximal weekly dose of injected semaglutide for diabetes treatment is 1.0 mg.)
At 68 weeks, mean reduction in body weight was significantly greater with semaglutide than with place…